Pathfast

"POC hs-cTn testing has significant potential to impact patient care in many settings; however, the clinical evidence supporting its use in practice remains limited. For services planning to implement POC testing, hs-cTn assays should be preferred, but the clinical impact is likely to depend on processes and issues that are particular to the local healthcare system."

"In conclusion, this study presented for the first time that the PATHFAST TB LAM Ag assay rapidly and reproducibly quantified LAM with high sensitivity, and that the LAM concentration correlated well with the bacterial load. This assay holds promise for the improved clinical management of patients on therapy, potentially serving as an alternative to culture methods. Continued research and validation efforts are imperative to establish its reliability and suitability across diverse settings."

"We demonstrated that there were no significant differences in plasma presepsin levels according to microbial isolates in blood culture. The major cause of the variability in presepsin levels during bloodstream infection might be the immunogenicity of each microorganism rather than the presence of LPS in the microorganism."

The study identifies presepsin as the most reliable biomarker for the early prediction of sepsis and multiorgan failure in patients with secondary peritonitis. While various cytokines (IL-6, IL-8, IL-10, HMGB-1, and MCP-1) show significant elevations in both peritoneal fluid and serum, their levels often fluctuate unpredictably and do not consistently correlate with disease severity. In contrast, presepsin levels measured at the time of surgery provide high diagnostic and prognostic value, allowing for better risk stratification within the first few hours. Ultimately, while the "cytokine storm" is central to the development of septic complications, systemic presepsin monitoring offers a more practical clinical tool for identifying high-risk patients than local peritoneal measurements.

"Cytokine production is the mainstay in developing sepsis and septic multiorgan failure in patients with secondary peritonitis; therefore, studying the dynamics of said cytokines seems of interest in finding tools to predict the development of sepsis or sepsis-related mortality. However, at the time, there seemed to be no clear correlation between the values of these cytokines and the development of complications."

"Elevated cTnI is common in patients with ATAAD, and is associated with increased 30-day mortality risk."

"Presepsin measurement by HISCL‐5000 showed reliable performance. Further clinical studies are required for the diagnosis and prognosis of sepsis."

"We validated the SF HNP1-3 diagnostic kit and demonstrated that SF and S HNP1-3 are promising biomarkers for distinguishing inflammatory from non-inflammatory joint diseases."

This study concludes that Presepsin (P-SEP) levels are artificially elevated by both renal impairment (Stage G3+) and sample agitation (e.g., pneumatic tubes). To prevent false-positive sepsis diagnoses, the authors propose the P-SEP/Creatinine (P-SEP/CRE) ratio as a superior index. Unlike raw P-SEP, this ratio remains stable across all CKD stages in non-infected patients but rises sharply during sepsis. With a reference range of 67–263, the P-SEP/CRE ratio provides a simple, accurate diagnostic tool for patients with kidney disease.

"The PATHFAST test highlighted the presence of infection in a very short time (15 minutes), and the presepsin could be considered an early biomarker in patients with cirrhosis. A greater number of patients are necessary to confirm these data."

"High‐sensitivity cardiac troponin assays matching the sensitivity of central laboratories are now available at the point of care [such as LSI Medience PATHFAST, Quidel TriageTrue, Siemens Atellica VTLi, and SpinChip SPINCHIP] and offer opportunities to develop new diagnostic care pathways for patients with acute and chronic coronary syndromes. At present, evidence for point of care testing in clinical practice is limited, but multiple prospective and randomised studies are underway that will inform how to safely and effectively integrate testing at the point of care into practice across multiple settings."

"We describe a good diagnostic accuracy of four hs-cTn assays using the assay-specific 99th percentile for detection of MI. Application of sex-specific 99th percentiles did neither affect diagnostic performance nor prognostic value significantly. Finally, values above the 99th percentile were associated with poor long-term outcome."

"The POC hs-cTnI-PATHFAST assay allows rapid and effective rule-out and rule-in of NSTEMI using both a 0/1h- and a 0/2h-algorithm with high NPV/sensitivity for rule-out and high PPV/specificity for rule-in."

"Whole blood can be used interchangeably with plasma for more convenient and less time and labor-consuming testing of hs-cTnI on the PATHFAST instrument."

"The ivisen IA‐1400 showed acceptable and promising performance in cTnI measurements using whole blood and plasma samples, with limited information in the clinical performance. The flexibility for sample selection using the internal centrifugation system is the main advantage of this point‐of‐care device."

"The timeliness of laboratory results is, in addition to accuracy and precision, one of the key indicators of laboratory performance, and at the same time has a significant impact on the course of the patient’s condition. It is therefore important that the laboratory strives to meet the expectations of clinicians regarding the time from the order to the result of the analysis."

"Our study provides the procedure and essential data to guide selection of a POC cTn device. Of the point‐of‐care devices, methods evaluated Radiometer AQT90 (cTnI and cTnT) and Pathfast might be considered."

"In conclusion, an ultra-high sensitive and label-free NI–SIS sensor was fabricated to detect cardiac-specific biomarkers at the early stage after AMI onset. NI–SIS sensor is equipped with a specially designed prism that provides the constant angle of incidence of probing beam close to NRC regardless of refractive index changes during operations. NI-prism improves the signal-to-noise ratio by eliminating a stray light reflected from the prism surface, resulting in ultra-high sensitive..."

"The data obtained seems to demonstrate the role of PSP in providing prognostic information in COVID-19 patients, allowing to identify, during the early phase of the monitoring, the patients suffering from a more severe disease which will be hospitalized for a more long time."

The study concludes that presepsin levels are highly dependent on renal function, showing a significant increase as GFR declines even in the absence of infection. By controlling for sample agitation and renal impairment, the researchers established a more accurate reference range of 59–153 pg/mL, which is notably lower than current standards. Consequently, clinical interpretation must strictly account for a patient's kidney function to avoid false-positive sepsis diagnoses.

"High-sensitivity troponin has become an essential emergency biomarker for diagnosing or ruling out an ACS. The establishment of a point of care biology related to the reorganization and fusion of laboratories raise a question about transferability of results between techniques. In this study, we propose to compare the bioclinical performances of high-sensitivity troponin measured by two different techniques on laboratory immunoanalyzer (Siemens Advia Centaur XPT) and on point of care device (Mitsubishi Pathfast). The assay of high-sensitivity troponin (n = 90 patients), according to our study, show consistent clinical results with both method."